Wolverine Trading, LLC Liquidia Corp Call Options Transaction History

Wolverine Trading, LLC

10 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q2 2024 Aug 14, 2024	SELL	$11.96 - $15.71 $34,684 - $45,559	-2,900 Reduced 12.89%	19,600 $235,000
Q1 2024 May 15, 2024	SELL	$11.35 - $16.73 $63,560 - $93,688	-5,600 Reduced 19.93%	22,500 $331,000
Q4 2023 Feb 14, 2024	BUY	$5.77 - $12.19 $70,971 - $149,937	12,300 Added 77.85%	28,100 $338,000
Q3 2023 Nov 15, 2023	BUY	$6.27 - $8.15 $13,167 - $17,115	2,100 Added 15.33%	15,800 $100,000
Q2 2023 Aug 23, 2023	BUY	$6.63 - $9.9 $3,315 - $4,950	500 Added 3.79%	13,700 $107,000
Q1 2023 May 15, 2023	BUY	$5.72 - $7.91 $75,504 - $104,412	13,200 New	13,200 $89,000
Q2 2022 Aug 15, 2022	BUY	$3.37 - $7.55 $37,407 - $83,805	11,100 New	11,100 $48,000
Q3 2021 Nov 12, 2021	SELL	$2.28 - $2.95 $38,076 - $49,265	-16,700 Closed	0 $0
Q2 2021 Aug 06, 2021	BUY	$2.51 - $3.11 $8,785 - $10,885	3,500 Added 26.52%	16,700 $49,000
Q1 2021 May 14, 2021	BUY	$2.42 - $3.6 $31,944 - $47,520	13,200 New	13,200 $34,000

163

36M

1.79M

380K

Ticker LQDA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 64,362,300
Market Cap $709M
Description
Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension. It also distributes generic treprostinil inje...

Get notified when there are updates to the investment portfolio of Wolverine Trading, LLC, based on Form 13F filings with the SEC.

Stay updated on Wolverine Trading, LLC with notifications on news.